US Patent 11,406,611: Scope of Claims and US Patent Landscape for (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid
US Patent 11,406,611 is directed to methods of treating intrahepatic cholestatic diseases using a single, tightly defined compound: (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid (free acid or salts), with narrower dependent claims specifying oral dosing, dose ranges (20-200 mg; narrower 50-100 mg), and a once-daily schedule. A second set of dependent limitations pivots to the L-lysine dihydrate salt form and repeats the same dosing windows and once-daily regimen.
What does claim scope cover in US 11,406,611?
Core independent claim: method-of-treatment with a single chemical identity
Claim 1 covers:
- A method of treating an intrahepatic cholestatic disease
- by administering to a subject in need thereof
- a therapeutically effective amount
- of the compound:
- (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid
- or a salt thereof
Key scope implications:
- The patent is a use claim (method-of-treatment), not a composition claim. In practical clearance work, this means infringement risk attaches to use in treating the specified disease class using the specified compound.
- The chemical identity is fully recited and is stereochemically constrained to the (R) enantiomer.
- “Intrahepatic cholestatic disease” is the only disease bucket. The claims do not list individual diseases (e.g., PBC/PSC/ICP), so the scope likely tracks whatever the specification defines as “intrahepatic cholestatic disease,” and how the term is construed during claim construction.
Independent claim carve-out: salt form
Claim 1 already captures:
- the free acid
- “or a salt thereof”
So the later L-lysine dihydrate claims are best read as narrower embodiments that tighten both the salt identity and the administration and dose schedule.
How do the dependent claims narrow enforceable boundaries?
Route of administration
- Claim 2: oral administration
This narrows the covered method to oral dosing of the claimed compound(s). If a clinician/investigator uses parenteral routes, claim 2 is avoided, but claim 1 may still be implicated depending on whether claim 1 already requires oral administration. Here, claim 1 does not. Therefore:
- Any oral method can fall under the dependent claim 2.
- Non-oral methods could still fall under claim 1 (unless claim 1 is construed to require oral dosing via claim dependency practices or spec-driven interpretation).
Dose window limitations
- Claim 3: daily dose 20-200 mg (when calculated as the free acid)
- Claim 4: daily dose 50-100 mg (same calculation convention)
These are classic enforceability levers:
- If an accused regimen is below 20 mg/day or above 200 mg/day, claim 3 is avoided.
- If it lands outside 50-100 mg/day, claim 4 is avoided.
- The claims explicitly state the dose is calculated “as” the free acid, which matters for salt-based formulations. That language typically prevents easy workarounds based on salt molecular weight differences.
Dosing frequency
- Claim 5: administered once/day
This provides a scheduling-specific exclusion:
- Twice-daily or multiple daily dosing can be outside claim 5 while still potentially falling under claim 1 or claim 3 depending on construction of the dependent dependency and whether frequency is required elsewhere (here, it is required only in claim 5 and claim 9).
What is the practical effect of the salt-specific claims?
L-lysine dihydrate salt embodiment
- Claim 6: oral administration of the (R) compound L-lysine dihydrate salt
- Claim 7: daily dose 20-200 mg (calculated as the free acid)
- Claim 8: daily dose 50-100 mg
- Claim 9: once/day
This set does two things simultaneously:
- It adds a salt identity requirement (L-lysine dihydrate).
- It duplicates the same oral, dose, and once/day constraints.
Because claim 1 already covers “salt thereof,” these dependent claims mostly tighten the salt identity plus regimen. For infringement mapping:
- A product using a different pharmaceutically acceptable salt could still implicate claim 1 but avoid claim 6-9.
- A product using L-lysine dihydrate salt with oral once-daily dosing in the claimed dose bands is the highest risk scenario.
What is the infringement “center of gravity”?
The claims concentrate risk on a narrow intersection of:
- Disease: intrahepatic cholestatic disease
- Compound: (R)-specific active
- Product attributes: oral route (for dependent claims) and potentially salt identity (L-lysine dihydrate for claims 6-9)
- Regimen: once/day and dose bands (20-200 mg; narrower 50-100 mg)
A regimen outside any one axis can move the case from:
- direct alignment with dependent claims
to reliance on the broader independent claim 1.
What does the patent landscape likely look like in the US?
Without the application bibliographic data (filing priority, assignee, related family members, continuations, and office action history), a complete US landscape cannot be validated with the required precision. The only defensible landscape analysis based strictly on the provided claim text is the structural claim-positioning in typical US filing strategies:
Likely landscape components to check (by search strategy, not by asserted existence)
- US composition patents for the free acid and/or salts
- Even though this patent is method-of-treatment, many families contain parallel claims to compositions or intermediates.
- US process patents for making the (R) enantiomer
- Stereoselective synthesis (chiral resolution or asymmetric synthesis) commonly receives separate protection.
- US salt-form patents
- Because L-lysine dihydrate is explicitly claimed, expect at least one member (possibly the same family) covering salt formation or the specific salt.
- US additional method claims
- Variants often exist that specify subtypes within intrahepatic cholestasis, broader dose ranges, or different dosing frequency.
- Product-specific Orange Book style clearance touchpoints
- If the compound reached commercial use, generic development typically triggers additional litigation and portfolio discovery around formulation and method-of-use.
Where are design-arounds most plausible on these claims (claim-chart level)?
Design around options are constrained because the independent claim 1 is broad on route and salt category but narrow on:
- disease category (“intrahepatic cholestatic disease”)
- compound identity (exact (R) structure)
- therapeutically effective amount (functional)
The dependent claims give the following practical carve-out levers:
- Avoid oral route (claims 2, 6-9)
- If administration is non-oral, dependent oral limitations are avoided.
- Change dose band
- Avoid 20-200 mg/day to steer clear of claims 3 and 7.
- Avoid 50-100 mg/day to steer clear of claims 4 and 8.
- Change dosing frequency
- Avoid once/day to steer clear of claims 5 and 9.
- Use a non-L-lysine dihydrate salt
- Claim 6-9 requires L-lysine dihydrate; claim 1 would still cover “a salt thereof,” so this is not a complete escape from claim 1.
- It is a way to reduce exposure to the narrower salt-specific claims.
Claim scope summary by axis
| Axis |
Covered in Claim 1 |
Added restrictions in dependent claims |
| Disease |
Intrahepatic cholestatic disease |
None specified in provided claims |
| Active |
(R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid; or salt |
None beyond salt identity in claims 6-9 |
| Route |
Not limited in claim 1 |
Oral in claims 2 and 6-9 |
| Dose (daily) |
Therapeutically effective |
20-200 mg in claims 3 and 7; 50-100 mg in claims 4 and 8 |
| Schedule |
Not limited in claim 1 |
Once/day in claims 5 and 9 |
| Salt identity |
“Salt thereof” generically |
L-lysine dihydrate specifically in claims 6-9 |
What to expect during claim construction and enforcement
The enforceability and breadth depend on several standard construction points that the provided claims already signal:
- Stereochemistry matters: “(R)” is not optional. A method using the racemate or (S) enantiomer should not meet the claim’s exact recitation.
- Dose calculation convention matters: the claims instruct that daily dose is calculated “as” the free acid, which reduces arguments based solely on using a different salt form to change the nominal milligram amount.
- Disease term breadth: “intrahepatic cholestatic disease” is a key construction target. Its scope can expand or contract based on specification and how courts treat medical taxonomy terms.
Key Takeaways
- US 11,406,611 is a method-of-treatment patent centered on treating intrahepatic cholestatic disease with a single stereochemically defined (R) compound (free acid or salts).
- Dependent claims tighten enforceability to oral administration, daily dose bands (20-200 mg; narrower 50-100 mg), and once-daily dosing.
- A specific formulation embodiment is claimed: (R) compound as the L-lysine dihydrate salt, with the same oral, dose, and once-daily restrictions.
- The highest infringement exposure is use of the (R) compound (or L-lysine dihydrate salt) in oral once-daily regimens within 20-200 mg/day (and especially 50-100 mg/day) for intrahepatic cholestatic disease.
FAQs
1) Does claim 1 require oral dosing?
No. Claim 1 does not limit route. Oral dosing is expressly required in claims 2 and 6-9.
2) Are dose limits mandatory for claim 1?
No. Claim 1 uses “therapeutically effective amount.” Dose bands are introduced in claims 3-5 and 7-9.
3) If a product uses L-lysine dihydrate but dosing is twice daily, is it outside the patent?
It is outside the once/day limitations of claims 5 and 9, but it may still fall under broader claim 1 (and possibly claim 3 or 7 if dose bands and oral route are met).
4) If a product uses a different salt of the same (R) compound, can it still infringe?
Yes. Claim 1 covers the compound “or a salt thereof,” so other salts of the same (R) compound remain within claim 1, though they may avoid the L-lysine-specific dependent claims.
5) What is the cleanest “carve-out” against dependent claims?
Operate outside at least one dependent axis: avoid oral route, avoid the specific daily dose windows, or avoid once-daily dosing.
References
[1] User-provided claim text for US Patent 11,406,611 (claims 1-9).
